Author

Bruce E. Sands 1

1 Icahn School of Medicine at Mount Sinai, New York, United States

A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE ORAL, GUT-RESTRICTED ALPHA4BETA7 INTEGRIN PEPTIDE ANTAGONIST PN-943 IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS FROM THE IDEAL STUDY

Scott Plevy, Bruce E. Sands, Julian Panés, Geert R. D'Haens, Vipul Jairath, Brian G. Feagan, Suneel Gupta, C. C. Hwang, Scott Lee, Alessandro Armuzzi, Walter Reinisch, Stefan Schreiber, William J. Sandborn

A POOLED SAFETY ANALYSIS FROM THE USTEKINUMAB CROHN?S DISEASE AND PSORIATIC DISEASES PHASE 2 AND 3 CLINICAL TRIAL PROGRAMS

Subrata Ghosh, Bruce E. Sands, Willem de Villiers, Elyssa Ott, Christopher Gasink, Yinghua Lang, Philippe Szapary, Douglas Jacobstein, Brian G. Feagan

A RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY TO EXPLORE THE EFFICACY OF ORAL GED-0301 (MONGERSEN) ON ENDOSCOPIC ACTIVITY AND CLINICAL EFFECTS IN BOTH TNF-NAIVE AND TNF-EXPERIENCED SUBJECTS WITH ACTIVE CROHN?S DISEASE

Brian G. Feagan, Bruce E. Sands, Guillermo Rossiter, Xiaobin Li, Keith Usiskin, Xiaojiang Zhan, Jean-Frederic Colombel

ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH IMPROVEMENTS IN CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING MIRIKIZUMAB

Marla C. Dubinsky, Remo Panaccione, James D Lewis, Bruce E. Sands, Toshifumi Hibi, Scott D. Lee, April Naegeli, Mingyang Shan, Linden Green, Nathan Morris, Vipin Arora, Alison Potts Bleakman, Ruth Belin, Simon Travis

ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH SIGNIFICANTLY IMPROVED INFLAMMATORY BOWEL DISEASE RELATED QUALITY OF LIFE IN A PHASE 2 TRIAL OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS

Marla C. Dubinsky, Scott D. Lee, Remo Panaccione, Maria T. Abreu, Severine Vermeire, Trevor Lissoos, Nathan Morris, Vipin Arora, Mingyang Shan, April Naegeli, Bruce E. Sands

ABX464 (OBEFAZIMOD) IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: AN INTERIM 48-WEEK SAFETY AND EFFICACY ANALYSIS FROM AN ONGOING 96-WEEK OPEN-LABEL MAINTENANCE PHASE 2B STUDY

Severine Vermeire, Bruce E. Sands, Sophie Biguenet, Hartmut Ehrlich, Paul GINESTE, Josianne Nitcheu, William J. Sandborn

AGREEMENT BETWEEN LOCALLY AND CENTRALLY REVIEWED MAYO ENDOSCOPIC SUBSCORES IN THE UNIFI STUDY OF USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS: CORROBORATION WITH FECAL CALPROTECTIN AND HISTOLOGY

Walter Reinisch, Colleen W. Marano, Allison Simi, John Lynch, Lenore Noonan, Hongyan Zhang, Bruce E. Sands, Daniel S. Mishkin

AN UPDATE ON THE ANALYSIS OF NON-MELANOMA SKIN CANCER IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAMME AS OF MAY 2019

Bruce E. Sands, Walter Reinisch, Julian Panés, Paulo Gustavo Kotze, Donna T Judd, Rajiv Mundayat, Nervin Lawendy

An update on the analysis of non-melanoma skin cancer in the tofacitinib ulcerative colitis programme

Bruce E. Sands, Millie Long, Leonard Baidoo, Walter Reinisch, Julian Panés, Arif Soonasra, Ronald D. Pedersen, Nervin Lawendy, Gary Chan

ANALYSIS OF NON-MELANOMA SKIN CANCER IN THE ULCERATIVE COLITIS PROGRAMME FOR TOFACITINIB

Bruce E. Sands, Millie D. Long, Leonard Baidoo, Walter Reinisch, Julian Panés, Chudy I. Nduaka, Arif Soonasra, Ronald D. Pedersen, Nervin Lawendy, Gary Chan, Gary S. Friedman, Chinyu Su

Item 1 - 10 / 84
1
2 3 4 5 6 7 8 9